Search results for "TRIPLE"

showing 10 items of 506 documents

Regio(ir)regular naphthalenediimide- and perylenediimide-bithiophene copolymers: How MO localization controls the bandgap

2016

Absorption spectra of regio(ir)regular naphthalenediimide (NDI)- and perylenediimide (PDI)-bithiophene (2T) donor/acceptor (D/A) copolymers are surprisingly similar despite cross-conjugation in the regioirregular structures. This result is traced back to largely localized frontier molecular orbitals (FMOs) as revealed by (time-dependent) DFT calculations. Interestingly, while the FMOs of the P(PDI-2T) copolymer are localized solely in the PDI units, they are predominantly localized in the respective D/A units of the P(NDI-2T) copolymer. The pronounced CT character of the lowest singlet state in P(NDI-2T) should give rise to a close lying CT triplet state, generating small singlet–triplet ga…

Absorption spectroscopyOrganic solar cellBand gapChemistry02 engineering and technologyGeneral Chemistry010402 general chemistry021001 nanoscience & nanotechnologyPhotochemistry01 natural sciencesAcceptor0104 chemical sciencesMaterials ChemistryCopolymerMolecular orbitalSinglet stateTriplet state0210 nano-technology
researchProduct

Multi-mycotoxin analysis in wheat semolina using an acetonitrile-based extraction procedure and gas chromatography–tandem mass spectrometry

2012

A new analytical method for the rapid and simultaneous determination of ten mycotoxins including patulin, zearalenone and eight trichothecenes (nivalenol, fusarenon-X, diacetoxyscirpenol, 3-acetyl-deoxynivalenol, neosolaniol, deoxynivalenol, T-2 and HT-2) in wheat semolina has been developed and optimized. Sample extraction and purification were performed with a modified QuEChERS-based (acronym of Quick, Easy, Cheap, Effective, Rugged and Safe) procedure and determined by gas chromatography (GC) coupled to triple quadrupole instrument (QqQ). This is the first paper on the application of GC-QqQ-MS/MS to analysis of mycotoxins. Careful optimization of the gas chromatography-tandem mass spectr…

AcetonitrilesChromatographyGas Chromatography/Tandem Mass SpectrometryCalibration curveFlourLiquid-Liquid ExtractionOrganic ChemistryAnalytical chemistryReproducibility of ResultsGeneral MedicineHydrogen-Ion ConcentrationMycotoxinsQuechersSensitivity and SpecificityBiochemistryGas Chromatography-Mass SpectrometryDiacetoxyscirpenolAnalytical ChemistryTriple quadrupole mass spectrometerPatulinchemistry.chemical_compoundchemistryTandem Mass SpectrometryGas chromatographyGas chromatography–mass spectrometryJournal of Chromatography A
researchProduct

Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway

2016

// Daniela Massihnia 1,* , Antonio Galvano 1,* , Daniele Fanale 1 , Alessandro Perez 1 , Marta Castiglia 1 , Lorena Incorvaia 1 , Angela Listi 1 , Sergio Rizzo 1 , Giuseppe Cicero 1 , Viviana Bazan 1 , Sergio Castorina 2,3,** and Antonio Russo 1,** 1 Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy 2 Fondazione Mediterranea “G.B. Morgagni”, Catania, Italy 3 Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy * These authors have contributed equally to this work ** Both the authors are last name Correspondence to: Antonio Russo, email: // Keywords : ER, HER2, PI3K/AKT/mTOR inhib…

Adult0301 basic medicineOncologymedicine.medical_specialtyPathologyAntineoplastic AgentsTriple Negative Breast NeoplasmsReviewTarget therapyPhosphatidylinositol 3-Kinases03 medical and health sciences0302 clinical medicineBreast cancerHER2Internal medicineDrug DiscoverymedicineCarcinomaHumansTriple negative breast cancerTarget therapyER; HER2; PI3K/AKT/mTOR inhibitor; Target therapy; Triple negative breast cancer; OncologySurvival rateProtein kinase BPI3K/AKT/mTOR pathwayTriple-negative breast cancerAgedClinical Trials as Topicbusiness.industryTOR Serine-Threonine KinasesAge FactorsMiddle Agedmedicine.diseaseOncogene Protein v-aktClinical trial030104 developmental biologyEROncology030220 oncology & carcinogenesisFemalePI3K/AKT/mTOR inhibitorbusinessSignal TransductionOncotarget
researchProduct

Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-…

2019

Altres ajuts: Agustí Barnadas: Honoraria: Pfizer. Consulting or Advisory Role: Pfizer, Novartis, Eli Lilly. Speakers'Bureau: Roche, Pfizer, Novartis, Genomic Health International. Travel, Accommodations, Expenses: Roche, Pfizer; Miguel A. Seguí: Consulting or Advisory Role: Roche, Pfizer, Novartis, Amgen, Eisai, Eli Lilly. Speakers' Bureau: Roche, Pfizer, Amgen. Research Funding: Roche (Inst), Novartis (Inst). Travel, Accommodations, Expenses: Roche, Pfizer, Novartis, Amgen. Operable triple-negative breast cancers (TNBCs) have a higher risk of relapse than non-TNBCs with standard therapy. The GEICAM/2003-11_CIBOMA/2004-01 trial explored extended adjuvant capecitabine after completion of sta…

Adult0301 basic medicineSubset AnalysisOncologyAntimetabolites AntineoplasticCancer Researchmedicine.medical_specialtyAxillary lymph nodesmedicine.medical_treatmentTriple Negative Breast NeoplasmsDisease-Free SurvivalCapecitabineYoung Adult03 medical and health sciences0302 clinical medicineInternal medicineHumansMedicineCapecitabineNeoadjuvant therapyTriple-negative breast cancerAgedChemotherapyTaxanebusiness.industryHazard ratioMiddle AgedNeoadjuvant Therapy030104 developmental biologymedicine.anatomical_structureOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisFemalebusinessmedicine.drug
researchProduct

Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry

2018

Brain metastases (BMs) have a major impact on life expectancy and quality of life for many breast cancer patients. Knowledge about treatment patterns and outcomes is limited.We analysed clinical data of 1712 patients diagnosed with BMs from breast cancer between January 2000 and December 2016 at 80 institutions.Median age at diagnosis of BMs was 56 years (22-90 years). About 47.8% (n = 732) of patients had HER2-positive, 21.4% (n = 328) had triple-negative and 30.8% (n = 471) had hormone receptor (HR)-positive, HER2-negative (luminal-like) primary tumours. The proportion of patients with HER2-positive BMs decreased comparing the years 2000-2009 with 2010-2015 (51%-44%), whereas the percenta…

AdultCancer Researchmedicine.medical_specialtyTime FactorsReceptor ErbB-2Posterior fossaAge at diagnosisBreast NeoplasmsTriple Negative Breast NeoplasmsYoung Adult03 medical and health sciences0302 clinical medicineBreast cancerQuality of lifeRisk FactorsGermanyInternal medicineBiomarkers TumormedicineHumansRegistriesskin and connective tissue diseasesAgedRetrospective StudiesAged 80 and overBrain Neoplasmsbusiness.industryMiddle Agedmedicine.diseaseTreatment OutcomeOncologyHormone receptor030220 oncology & carcinogenesisCohortLife expectancyFemalePrimary breast cancerbusiness030217 neurology & neurosurgeryEuropean Journal of Cancer
researchProduct

BRCA1 promoter methylation in peripheral blood is associated with the risk of triple‐negative breast cancer

2019

Methylation of the promoter of the BRCA1 gene in DNA derived from peripheral blood cells is a possible risk factor for breast cancer. It is not clear if this association is restricted to certain types of breast cancer or is a general phenomenon. We evaluated BRCA1 methylation status in peripheral blood cells from 942 breast cancer patients and from 500 controls. We also assessed methylation status in 262 paraffin‐embedded breast cancer tissues. Methylation status was assessed using methylation‐sensitive high‐resolution melting and was categorized as positive or negative. BRCA1 methylation in peripheral blood cells was strongly associated with the risk of triple‐negative breast cancer (TNBC)…

AdultOncologyCancer Researchmedicine.medical_specialtyConcordanceTriple Negative Breast Neoplasms03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBreast cancerInternal medicineBiomarkers TumormedicineHumansGenetic Predisposition to DiseaseBreastRisk factorPromoter Regions Geneticskin and connective tissue diseasesTriple-negative breast cancerAgedAged 80 and overBRCA1 Proteinbusiness.industryMethylationOdds ratioDNA MethylationMiddle Agedmedicine.diseaseOncologychemistryCase-Control Studies030220 oncology & carcinogenesisBiomarker (medicine)FemalebusinessDNAFollow-Up StudiesInternational Journal of Cancer
researchProduct

Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Posit…

2015

Purpose Modulation of immunologic interactions in cancer tissue is a promising therapeutic strategy. To investigate the immunogenicity of human epidermal growth factor receptor 2 (HER2) –positive and triple-negative (TN) breast cancers (BCs), we evaluated tumor-infiltrating lymphocytes (TILs) and immunologically relevant genes in the neoadjuvant GeparSixto trial. Patients and Methods GeparSixto investigated the effect of adding carboplatin (Cb) to an anthracycline-plus-taxane combination (PM) on pathologic complete response (pCR). A total of 580 tumors were evaluated before random assignment for stromal TILs and lymphocyte-predominant BC (LPBC). mRNA expression of immune-activating (CXCL9, …

AdultOncologyCancer Researchmedicine.medical_specialtyStromal cellReceptor ErbB-2medicine.medical_treatmentAntineoplastic AgentsTriple Negative Breast NeoplasmsCarboplatinchemistry.chemical_compoundLymphocytes Tumor-InfiltratingPredictive Value of TestsInternal medicineBiomarkers TumormedicineHumansAgedRandomized Controlled Trials as TopicChemotherapybusiness.industryTumor-infiltrating lymphocytesCancerFOXP3Middle AgedPrognosismedicine.diseaseNeoadjuvant TherapyCarboplatin3. Good healthCD8AGene Expression Regulation NeoplasticOncologychemistryChemotherapy AdjuvantCXCL9FemalebusinessJournal of Clinical Oncology
researchProduct

Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial

2021

Introduction: Large and consistent evidence supports the use of eribulin mesylate in clinical practice in third or later line treatment of metastatic triple negative breast cancer (mTNBC). Conversely, there is paucity of data on eribulin efficacy in second line treatment. Methods: We investigated outcomes of 44 mTNBC patients treated from 2013 through 2019 with second line eribulin mesylate in a multicentre retrospective study involving 14 Italian oncologic centres. Results: Median age was 51 years, with 11.4% of these patients being metastatic at diagnosis. Median overall survival (OS) and progression free survival (PFS) from eribulin starting were 11.9 (95%CI: 8.4-15.5) and 3.5 months (95…

AdultOncologyEribulin Mesylatemedicine.medical_specialtyeribulin mesylatemedicine.medical_treatmentTriple Negative Breast Neoplasmschemotherapytriple negative metastatic breast cancer03 medical and health scienceschemistry.chemical_compound0302 clinical medicineadjuvantInternal medicineAntineoplastic Combined Chemotherapy Protocols80 and overmedicineHumansChemotherapy; Efficacy outcomes; Eribulin mesylate; Toxicity outcomes; Triple negative metastatic breast cancerProgression-free survivalFuransAdverse effectTriple-negative breast cancerAgedNeoplasm StagingRetrospective StudiesAged 80 and overChemotherapybusiness.industryRetrospective cohort studyGeneral MedicineKetonesMiddle Agedmedicine.diseaseMetastatic breast cancerNeoadjuvant TherapyProgression-Free SurvivalchemistryChemotherapy AdjuvantFemale030211 gastroenterology & hepatologytoxicity outcomesefficacy outcomeschemotherapy; efficacy outcomes; eribulin mesylate; toxicity outcomes; triple negative metastatic breast cancer; adult; aged; aged; 80 and over; antineoplastic combined chemotherapy protocols; chemotherapy; adjuvant; female; furans; humans; ketones; middle aged; neoadjuvant therapy; neoplasm staging; progression-free survival; retrospective studies; triple negative breast neoplasmsbusinessResearch PaperEribulinInternational Journal of Medical Sciences
researchProduct

Fetus acardius: two- and three-dimensional ultrasonographic diagnoses.

2001

Objective. To determine whether ultrasonographic detection of acardiac fetuses and diagnostic accuracy of related malformations improve with complementary use of two-dimensional ultrasonography, three-dimensional ultrasonography, and Doppler scanning. Methods. Three pregnant women with multifetal gestations who were found to have discordant fetuses on initial two-dimensional ultrasonographic scanning were subsequently scanned with three-dimensional ultrasonography and color Doppler ultrasonography. Results. Although the possibility of acardiac fetuses was entertained in all cases after two-dimensional ultrasonographic scanning, the diagnosis was confirmed, and the accuracy and extent of fet…

Adultmedicine.medical_specialtyTriplet gestationUltrasonography PrenatalFetal HeartPregnancymedicineHumansRadiology Nuclear Medicine and imagingMedical diagnosisArthrogryposisFetusPregnancyRadiological and Ultrasound TechnologyGastroschisisbusiness.industryObstetricsMiddle Agedmedicine.diseasePregnancy Trimester FirstGestationFemalePregnancy Multiplemedicine.symptomUltrasonographybusinessJournal of Ultrasound in Medicine
researchProduct

Semantically enriched informed environment for multi-agent simulation : application to simulation in 3D virtual environment

2014

This thesis focuses on multi-agent simulation applied to the simulation of individuals in virtual 3D buildings. To do this, our work suggests to capitalize on the experience gained in the field of semantic web ontologies and inference engines to facilitate the design and development of intelligent behavior for agents operating in virtual worlds. The goal is to provide to agents a generic approach to managing their representation of the world and reason about this representation. For this, the central problem is based on the definition of a decidable ontology modeling all of the knowledge contained in the virtual 3D environment to enrich semantically the environment of a multi-agent simulati…

Agents intelligents[INFO.INFO-AI] Computer Science [cs]/Artificial Intelligence [cs.AI]Multi-agents based simulations[INFO.INFO-WB] Computer Science [cs]/WebOntology[INFO.INFO-WB]Computer Science [cs]/WebSmart agentsOntologieSmart environment[INFO.INFO-AI]Computer Science [cs]/Artificial Intelligence [cs.AI]ReasonerTriplestoreRaisonneurEnvironnement intelligentWeb sémantiqueSemantic webSimulation multi-agents
researchProduct